The Consideration of Antiplatelet Therapy after DES Implantation in HBR Patients from the MASTER DAPT Study
In the MASTER DAPT study, in patients with a high bleeding risk (HBR) who received a Ultimaster sirolimus-eluting stent (U-SES), one month of dual antiplatelet therapy (DAPT) was compared to continued standard DAPT. It was non-inferior in assessing NACE (all-cause mortality, MI, stroke, and BARC 3/5 severe bleeding) and MACCE (all-cause mortality, MI, or stroke), but the rate of BARC 2, 3, or 5 severe/clinically-impacted non-severe bleeding was lower.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
